SCHEMBL6962464

SCHEMBL6962464

COC(=O)C1Cc2ccccc2CN1CCCN1c2ccccc2CCc2ccccc21

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A4 P31645 7/20 0.46
DRD2 P14416 7/20 0.46
DRD3 P35462 7/20 0.46
SLC6A2 P23975 4/20 0.46
HTR2A P28223 4/20 0.46
CHRM1 P11229 4/20 0.46
CHRM3 P20309 4/20 0.46
CHRM2 P08172 3/20 0.46
ADRA2B P18089 3/20 0.46
ADRA2C P18825 3/20 0.46
HTR2C P28335 3/20 0.46
ADRA1A P35348 3/20 0.46
HRH1 P35367 3/20 0.46
OPRK1 P41145 3/20 0.46
SLC6A3 Q01959 3/20 0.46
KCNH2 Q12809 3/20 0.46
CYP3A4 P08684 2/20 0.46
SLC22A2 O15244 2/20 0.46
SLC22A1 O15245 2/20 0.46
SLC22A3 O75751 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5500239 0.86 HTR2A (0.47) SLC6A4DRD2DRD3SLC6A2HTR2A
Hydrochloric Acid SCHEMBL6962899 0.85 HTR2A (0.46) SLC6A4DRD2DRD3SLC6A2HTR2A
SCHEMBL5740070 0.79 MMP8 (0.43) CYP1A2HTTNPSR1
SCHEMBL3240479 0.79 MMP9 (0.43)
SCHEMBL6958438 0.78 HTR2A (0.44) SLC6A4DRD2DRD3SLC6A2HTR2A
SCHEMBL28058014 0.78 MMP2 (0.38)
SCHEMBL6369530 0.78 NR1D1 (0.45) CYP1A2HTTNPSR1
SCHEMBL12125014 0.78 NR1D1 (0.45) CYP1A2HTTNPSR1
SCHEMBL7332043 0.75 CYP19A1 (0.42) DRD2CYP1A2NPSR1DRD4
SCHEMBL6969671 0.75 DRD3 (0.46) SLC6A4DRD2DRD3SLC6A2HTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6613791-B1 Treating migraine, neurogenic inflammation, rheumatoid arthritis or insulin resistance NOVO NORDISK A/S (DK) 2003-09-02 US disclosed
EP-0820451-B1 NOVEL HETEROCYCLIC COMPOUNDS NOVO NORDISK AS (DK) 2003-01-15 EP disclosed
US-6239148-B1 TREATMENT OF PAINFUL, HYPERALGESIC AND/OR INFLAMMATORY CONDITIONS IN WHICH C-FIBERS PLAY A ROLE BY ELICITING NEUROGENIC PAIN, INSULIN RESISTANCE IN DIABETES MELLITUS OR AGING, INHIBIT INSULIN ANTAGONIZING PEPTIDE, NOVO NORDISK A/S (DK) 2001-05-29 US disclosed
US-6166009-A N-substituted azaheterocyclic carboxylic acids and esters thereof NOVO NORDISK A/S (DK) 2000-12-26 US disclosed
US-6110913-A ANTIINFLAMMATORY AGENTS, ANALGESICS NOVO NORDISK A/S (DK) 2000-08-29 US disclosed
US-6071901-A TREATING PAIN, HYPERALGESIA AND/OR INFLAMMATORY CONDITIONS IN WHICH C-FIBERS PLAY A PATHOPHYSIOLOGICAL ROLE; INHIBITION OF NEUROGENIC INFLAMMATION INVOLVING THE RELEASE OF NEURO-PEPTIDE FROM PERIPHERAL AND CENTRAL ENDINGS OF SENSORY NERVES NOVO NORDISK A/S (DK) 2000-06-06 US disclosed
EP-0820451-A1 NOVEL HETEROCYCLIC COMPOUNDS NOVO NORDISK A/S (DK) 1998-01-28 EP disclosed
WO-1996031498-A1 NOVEL HETEROCYCLIC COMPOUNDS NOVO NORDISK A/S (DK) 1996-10-10 WO disclosed